IUrisure
Urine DNA Methylation Detection Kit for Urothelial Carcinoma
IUrisure is a product that detects the methylation of the AL021918.2 and VIM genes in exfoliated urothelial cells from urine. It can screen for urothelial carcinoma, including bladder cancer, ureteral cancer and renal pelvis cancer, with bladder cancer being the most prevalent among urothelial malignancies.
What is Urothelial Carcinoma?
Urothelial carcinoma is cancer that starts in urothelium, the tissue that lines parts of urinary system. Urothelial carcinoma accounts for about 90% of all cases of bladder cancer and 7% of all cases of kidney cancer, including cancer in renal pelvis and ureter. Bladder and kidney cancers caused by urothelial carcinoma have similar symptoms. They also have similar prognoses – caught early on, these cancers are easily treated, but often come back.
Who should get this test?
People with hematuria
80%-90% of bladder cancer patients first discover abnormalities as hematuria.
Chronic infection
Chronic urinary tract infections and kidney stones may significantly increase the risk of bladder cancer.
History of urothelial carcinoma
Environmental and occupational
Smoking and Exposure to carcinogens
Long-term irritation by foreign objects
e.g., indwelling catheters, stones.
Family history of bladder cancer
Kit Components of IUrisure
Urine DNA Extraction and Bisulfite Conversion Kit
Urine DNA Methylation Detection Kit for Urothelial Carcinoma (Real-time PCR)
Advantage of IUrisure
Non-invasive
Performed on a urine sample, reducing the number of recurrent cystoscopies.
Highly accurate
Overall Sensitivity: 92.94%, Specificity: 92.83%.
Widely applications
For hematuria triage, treatment assessment & recurrence surveillance.
Conveniently collected
Urine can be collected at the hospital or at home.
Fast result
Results available within 4.5h since sample processing.
Early Intervention
Enables timely treatment by detecting molecular changes before clinical symptoms.
Clinical Performance
The study included a total of 1,571 valid samples for statistical analysis, comprising 637 samples of UC and 934 samples of non-UC. The results showed a sensitivity of 92.94% and a specificity of 92.83%.
Testing Procedures
Urine sample collection
Pretreatment and extraction
Bisulfite conversion and purification
qPCR procedure
